Digestive Diseases and Sciences

, Volume 52, Issue 11, pp 3245–3250

Serum Concentrations of Insulin-Like Growth Factor-I (IGF-I) as a Marker of Liver Fibrosis in Patients With Chronic Hepatitis C

  • Vicente Lorenzo-Zúñiga
  • Ramon Bartolí
  • Helena Masnou
  • Silvia Montoliu
  • Rosa M a Morillas
  • Ramon Planas
Original Article

Abstract

Liver biopsy was until recently the only way of evaluating liver fibrosis. Noninvasive tests for hepatic fibrosis, without potential risks, are desired by clinicians as well as patients. Insulin-like growth factor-I (IGF-I) synthesis is disturbed in liver fibrosis and reflects the severity of the clinical stage. We assessed serum IGF-I levels in patients with chronic hepatitis C (CHC) to correlate with liver fibrosis and antiviral therapy. Forty patients with CHC and persistently abnormal alanine aminotransferase values were enrolled and treated with peginterferon α-2a 180 μg per week plus ribavirin for 24 (n=20) or 48 (n=20) weeks. All patients underwent liver biopsy before treatment (METAVIR fibrosis stage F0, n=13; F1–F2, n=14; F3, n=7; F4, n=6). Serum IGF-I was measured at baseline, at the end of treatment period, and 24 weeks after finishing treatment. Mean IGF-I values were significantly lower in patients with advanced fibrosis (F4, 65.9±17.9 ng/mL) than in the others (F0, 145.2±47.1; F1–F2, 150.3±89.6; and F3, 121.4±35.2 ng/mL; P < .05). Serum IGF-I levels increased during combined therapy, being this increment markedly higher in patients with sustained virologic response. In conclusion, IGF-I synthesis is disturbed in CHC and reflects the severity of the liver fibrosis. Combined therapy improves serum IGF-I levels. IGF-I could represent a good, noninvasive marker of liver fibrosis.

Keywords

Serum IGF-I levels Chronic hepatitis C Liver fibrosis Combined therapy 

References

  1. 1.
    NIH Consensus Statement on Management of Hepatitis C (2002) Hepatology 36:S3–S20Google Scholar
  2. 2.
    Strader DB, Wright T, Thomas DL, Seef LB (2004) AALSD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRefGoogle Scholar
  3. 3.
    Dienstag JL (2002) The role of liver biopsy in chronic hepatitis C. Hepatology 36:S152–S160PubMedCrossRefGoogle Scholar
  4. 4.
    Castera L, Negre I, Samii K, Buffet C (1999) Pain experienced during percutaneous liver biopsy. Hepatology 30:1529–1530PubMedCrossRefGoogle Scholar
  5. 5.
    Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97:2614–2618PubMedCrossRefGoogle Scholar
  6. 6.
    Bedossa P, Dargère D, Paradise V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38:1449–1457PubMedGoogle Scholar
  7. 7.
    Fontana RJ, Lok AS (2002) Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 36:S57–S64PubMedCrossRefGoogle Scholar
  8. 8.
    Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C (1997) Noninvasive diagnosis of hepatic fibrosis or cirrhosis.Gastroenterology 113:1609–1616PubMedCrossRefGoogle Scholar
  9. 9.
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis. C Hepatology 38:518–526PubMedCrossRefGoogle Scholar
  10. 10.
    Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069–1075Google Scholar
  11. 11.
    Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36:986–992PubMedGoogle Scholar
  12. 12.
    Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D (2003) Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18:253–257PubMedCrossRefGoogle Scholar
  13. 13.
    Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J (1996) Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 42:558–563PubMedGoogle Scholar
  14. 14.
    Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R (2004) Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10:429–434PubMedCrossRefGoogle Scholar
  15. 15.
    Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29:1705–1713PubMedCrossRefGoogle Scholar
  16. 16.
    Sara VR, Hall K (1990) Insulin-like growth factors and their binding proteins. Physiol Rev 70:591–614PubMedGoogle Scholar
  17. 17.
    Schimpff RM, Lebrec D, Donnadieu M (1977) Somatomedin production in normal adults and cirrhotic patients. Acta Endocrinol 86:355–62PubMedGoogle Scholar
  18. 18.
    Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMedCrossRefGoogle Scholar
  19. 19.
    Picardi A, Deoliveira AC, Muguerza B, Tosar A, Quiroga J, Castilla-Cortázar I, Santidrián S, Prieto J (1997) Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol 26:191–202PubMedCrossRefGoogle Scholar
  20. 20.
    Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A (2003) Serum concentrations of insulin-like growth factor-I (IGF-I) in patient with liver cirrhosis. Hepatogastroenterology 50:814–6PubMedGoogle Scholar
  21. 21.
    Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y, Imura H (1992) Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis. Metabolism 41:377–381PubMedCrossRefGoogle Scholar
  22. 22.
    Møller S, Becker U, Juul A, Skakkebbæk NE, Christensen E, EMALD Group (1996) Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol-induced liver disease. Hepatology 23:1073–8PubMedCrossRefGoogle Scholar
  23. 23.
    Granada ML, Murillo J, Lucas A, Salinas I, Llopis MA, Castells I, Foz M, Sanmartí A (2000) Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ration and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population. Eur J Endocrinology 142:243–253CrossRefGoogle Scholar
  24. 24.
    Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 24:289–293PubMedCrossRefGoogle Scholar
  25. 25.
    Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber R (2005) Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41:1376–1382PubMedCrossRefGoogle Scholar
  26. 26.
    Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H (2003) Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer 88:733–739PubMedCrossRefGoogle Scholar
  27. 27.
    Inaba T, Saito H, Inoue T, Han I, Furukawa S, Matsuda T, Ikeda S, Muto T (1999) Growth hormone/insulin-like growth factor I axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy. J Hepatol 31:271–276PubMedCrossRefGoogle Scholar
  28. 28.
    Castilla-Cortázar I, García M, Muguerza B, Quiroga J, Pérez R, Santidrián S, Prieto J (1997) Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 113:1682–1691PubMedCrossRefGoogle Scholar
  29. 29.
    Tong MJ, el-Farra NS, Reikes AR, Co RL (1995) Clinical outcomes after transfusion-associated hepatitis C. N Eng J Med 332:1463–6CrossRefGoogle Scholar
  30. 30.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr , Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Hoffman J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982PubMedCrossRefGoogle Scholar
  31. 31.
    Hadzjyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HJ, Bernstein D, Rizzeto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomised study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355Google Scholar
  32. 32.
    Mann MP, McHutchinson JG, Gordon SC, Rusgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2002) Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965CrossRefGoogle Scholar
  33. 33.
    National Institutes of Health Consensus Development Conference (2002) National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Hepatology 36(suppl 1):S3–S20Google Scholar
  34. 34.
    Poynard T, McHutchison J, David GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131–1137PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Vicente Lorenzo-Zúñiga
    • 1
  • Ramon Bartolí
    • 1
  • Helena Masnou
    • 1
  • Silvia Montoliu
    • 1
  • Rosa M a Morillas
    • 1
  • Ramon Planas
    • 1
  1. 1.Hepatology Unit, Department of GastroenterologyHospital Universitari Germans Trias i Pujol, Carretera del Canyet s/nBadalonaSpain

Personalised recommendations